IDEXX Laboratories, Inc. $IDXX Shares Bought by Axa S.A.

Axa S.A. raised its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 178.5% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 59,141 shares of the company’s stock after acquiring an additional 37,907 shares during the quarter. Axa S.A. owned 0.07% of IDEXX Laboratories worth $31,720,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Opal Wealth Advisors LLC purchased a new position in IDEXX Laboratories in the 2nd quarter worth about $29,000. Ameritas Advisory Services LLC purchased a new position in shares of IDEXX Laboratories in the second quarter worth approximately $36,000. Elevation Point Wealth Partners LLC acquired a new stake in shares of IDEXX Laboratories during the second quarter valued at approximately $36,000. WPG Advisers LLC purchased a new stake in shares of IDEXX Laboratories in the 1st quarter valued at approximately $37,000. Finally, NewSquare Capital LLC boosted its stake in IDEXX Laboratories by 87.5% in the 2nd quarter. NewSquare Capital LLC now owns 75 shares of the company’s stock worth $40,000 after purchasing an additional 35 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on IDXX shares. Jefferies Financial Group reissued a “buy” rating and set a $830.00 price target on shares of IDEXX Laboratories in a research report on Tuesday, November 4th. JPMorgan Chase & Co. upped their target price on IDEXX Laboratories from $675.00 to $775.00 and gave the company an “overweight” rating in a report on Tuesday, November 4th. Morgan Stanley raised their price target on shares of IDEXX Laboratories from $765.00 to $805.00 and gave the stock an “overweight” rating in a report on Tuesday, November 4th. Barclays assumed coverage on shares of IDEXX Laboratories in a research report on Monday. They set an “overweight” rating and a $850.00 price objective on the stock. Finally, Stifel Nicolaus set a $775.00 target price on shares of IDEXX Laboratories in a research report on Monday, November 3rd. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, IDEXX Laboratories currently has an average rating of “Moderate Buy” and a consensus target price of $763.50.

IDEXX Laboratories Trading Down 1.1%

Shares of NASDAQ:IDXX opened at $699.06 on Wednesday. The company has a market cap of $55.82 billion, a P/E ratio of 55.44, a P/E/G ratio of 4.22 and a beta of 1.67. The stock’s 50-day moving average is $678.66 and its 200-day moving average is $616.60. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $769.98. The company has a debt-to-equity ratio of 0.24, a quick ratio of 0.87 and a current ratio of 1.18.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Monday, November 3rd. The company reported $3.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.14 by $0.08. IDEXX Laboratories had a net margin of 24.65% and a return on equity of 67.78%. The business had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter last year, the company posted $2.80 earnings per share. IDEXX Laboratories’s quarterly revenue was up 13.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Equities research analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Insider Buying and Selling

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 9,425 shares of the firm’s stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $703.34, for a total value of $6,628,979.50. Following the completion of the sale, the executive vice president owned 21,149 shares in the company, valued at approximately $14,874,937.66. This trade represents a 30.83% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.98% of the stock is currently owned by company insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.